Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Pacing Clin Electrophysiol ; 47(3): 440-444, 2024 03.
Article in English | MEDLINE | ID: mdl-37310078

ABSTRACT

Congenitally corrected transposition of the great arteries (CCTGA) is a rare congenital heart disease which may present sudden cardiac death presumably due to malignant ventricular tachycardia (VT). In patients with congenital heart disease, knowledge of arrhythmogenic substrate is crucial for planning an ablation procedure. We present the first description of the arrhythmogenic endocardial substrate of a non-iatrogenic scar-related VT in a patient with CCTGA.


Subject(s)
Heart Defects, Congenital , Tachycardia, Ventricular , Transposition of Great Vessels , Adult , Humans , Congenitally Corrected Transposition of the Great Arteries , Transposition of Great Vessels/complications , Transposition of Great Vessels/surgery , Tachycardia, Ventricular/surgery , Arteries
2.
Cardiovasc Revasc Med ; 59: 93-98, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37723011

ABSTRACT

INTRODUCTION: Clinical events may occur after percutaneous coronary intervention (PCI), particularly in complex lesions and complex patients. The optimization of PCI result, using pressure guidewire and intracoronary imaging techniques, may reduce the risk of these events. The hypothesis of the present study is that the clinical outcome of patients with indication of PCI and coronary stent implantation that are at high risk of events can be improved with an unrestricted use of intracoronary tools that allow PCI optimization. METHODS AND ANALYSIS: Observational prospective multicenter international study, with a follow-up of 12 months, including 1064 patients treated with a cobalt­chromium everolimus-eluting stent. Inclusion criteria include any of the following: Lesion length > 28 mm; Reference vessel diameter < 2.5 mm or > 4.25 mm; Chronic total occlusion; Bifurcation with side branch ≥2.0 mm;Ostial lesion; Left main lesion; In-stent restenosis; >2 lesions stented in the same vessel; Treatment of >2 vessels; Acute myocardial infarction; Renal insufficiency; Left ventricular ejection fraction <30 %; Staged procedure. The control group will be comprised by a similar number of matched patients included in the "extended risk" cohort of the XIENCE V USA study. The primary endpoint will be the 1-year rate of target lesion failure (TLF) (composite of ischemia-driven TLR, myocardial infarction (MI) related to the target vessel, or cardiac death related to the target vessel). Secondary endpoints will include overall mortality, cardiovascular mortality, acute myocardial infarction, TVR, TLR, target vessel failure, and definitive or probable stent thrombosis at 1 year. IMPLICATIONS: The ongoing OPTI-XIENCE study will contribute to the growing evidence supporting the use of intra-coronary imaging techniques for stent optimization in patients with complex coronary lesions.


Subject(s)
Coronary Artery Disease , Drug-Eluting Stents , Myocardial Infarction , Percutaneous Coronary Intervention , Humans , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/therapy , Coronary Artery Disease/etiology , Myocardial Infarction/etiology , Percutaneous Coronary Intervention/adverse effects , Prospective Studies , Prosthesis Design , Sirolimus , Stroke Volume , Treatment Outcome , Ventricular Function, Left
3.
Cardiovasc Diagn Ther ; 13(5): 792-804, 2023 Oct 31.
Article in English | MEDLINE | ID: mdl-37941845

ABSTRACT

Background: Drug-eluting stents (DES) are considered the therapy of choice in ST-segment elevation myocardial infarction (STEMI); however, a low persistent rate of revascularizations and stent thrombosis exist over the time. We have previously shown that a paclitaxel (PTX)-drug-coated balloon (DCB) after a bare-metal stent (BMS) implantation (DCB-combined strategy) yields superior angiographic and clinical results compared to BMS in the short term. However, the long-term safety and efficacy of this approach remain uncertain. Methods: An 8-year clinical follow-up was conducted on patients enrolled in the randomized PEBSI-1 trial (NCT01839890). The original trial included patients who suffered a STEMI, patients were randomly assigned to receive a DCB-combined strategy or BMS only and the primary endpoint was in-stent late luminal loss (LLL) at 9-month follow-up. After the completion of this study, death, myocardial re-infarction, ischemia-driven repeated revascularizations included target lesion revascularization (TLR) and target vessel revascularization (TVR), and stent thrombosis, were assessed by yearly contact by a clinical visit, telephone or by electronic records. These outcomes were adhered to ARC-2 criteria. Results: The rate of incomplete follow-up was very low, with only 3 out of 111 patients (2.7%) in the DCB-combined strategy group and 1 out of 112 patients (0.9%) in the BMS group. At 8 years there were a lower rate of TVR [3.7% vs. 14.3%; hazard ratio (HR): 0.243; 95% confidence interval (CI): 0.081-0.727; P=0.006], and a trend towards lower TLR (2.8% vs. 8.9%; HR: 0.300; 95% CI: 0.083-1.090; P=0.052) in the DCB-combined strategy group. No statistical difference between the DCB-combined strategy and BMS groups were found for all causes of death, deaths from cardiovascular disease, reinfarctions or stent thrombosis. Notably in the DCB-combined strategy group, no episode of stent thrombosis occurred after the first year. Similarly, there were no cardiovascular deaths, TVR and TLR in the DCB-combined strategy group after 5 years. In contrast, during the period from year 5 to 8, the BMS group experienced an additional cardiovascular death, as well as one case of TVR, one case of TLR, and one case of stent thrombosis. Conclusions: In STEMI patients, the DCB-combined strategy maintains its safety and clinical efficacy over time. Our rates of TVR, TLR, and very late stent thrombosis (VLST) at very long-term are the lowest ever found in a STEMI trial. Further studies are warranted to assess the potential superiority of this novel strategy as compared with new-generation DES to prevent very late events in these patients. Trial Registration: ClinicalTrials.gov; identifier: NCT01839890.

4.
JACC Cardiovasc Interv ; 16(10): 1208-1217, 2023 05 22.
Article in English | MEDLINE | ID: mdl-37225292

ABSTRACT

BACKGROUND: Coronary obstruction (CO) following transcatheter aortic valve replacement (TAVR) is a life-threatening complication, scarcely studied. OBJECTIVES: The authors analyzed the incidence of CO after TAVR, presentation, management, and in-hospital and 1-year clinical outcomes in a large series of patients undergoing TAVR. METHODS: Patients from the Spanish TAVI (Transcatheter Aortic Valve Implantation) registry who presented with CO in the procedure, during hospitalization or at follow-up were included. Computed tomography (CT) risk factors were assessed. In-hospital, 30-day, and 1-year all-cause mortality rates were analyzed and compared with patients without CO using logistic regression models in the overall cohort and in a propensity score-matched cohort. RESULTS: Of 13,675 patients undergoing TAVR, 115 (0.80%) presented with a CO, mainly during the procedure (83.5%). The incidence of CO was stable throughout the study period (2009-2021), with a median annual rate of 0.8% (range 0.3%-1.3%). Preimplantation CT scans were available in 105 patients (91.3%). A combination of at least 2 CT-based risk factors was less frequent in native than in valve-in-valve patients (31.7% vs 78.3%; P < 0.01). Percutaneous coronary intervention was the treatment of choice in 100 patients (86.9%), with a technical success of 78.0%. In-hospital, 30-day, and 1-year mortality rates were higher in CO patients than in those without CO (37.4% vs 4.1%, 38.3% vs 4.3%, and 39.1% vs 9.1%, respectively; P < 0.001). CONCLUSIONS: In this large, nationwide TAVR registry, CO was a rare, but often fatal, complication that did not decrease over time. The lack of identifiable predisposing factors in a subset of patients and the frequently challenging treatment when established may partly explain these findings.


Subject(s)
Coronary Occlusion , Transcatheter Aortic Valve Replacement , Humans , Transcatheter Aortic Valve Replacement/adverse effects , Treatment Outcome , Catheters , Registries
5.
Int J Cardiol ; 338: 63-71, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34062196

ABSTRACT

BACKGROUND: We sought to investigate the antithrombotic regimens applied and their prognostic effects in patients over 75 years old with atrial fibrillation (AF) after revascularization with drug-eluting stents (DES). METHODS: Retrospective registry in 20 centers including patients over 75 years with AF treated with DES. A primary endpoint of MACCE and a co-primary endpoint of major bleeding by ISTH criteria were considered at 12 months. RESULTS: A total of 1249 patients (81.1 ±â€¯4.2 years, 33.1% women, 66.6% ACS, 30.6% complex PCI) were included. Triple antithrombotic therapy (TAT) was prescribed in 81.7% and dual antithrombotic therapy (DAT) in 18.3%. TAT was based on direct oral anticoagulants (DOAC) in 48.4% and maintained for only 1 month in 52.2%, and DAT included DOAC in 70.6%. Primary endpoint of MACCE was met in 9.6% and primary endpoint of major bleeding in 9.4%. TAT was significantly associated with more bleeding (10.2% vs. 6.1%, p = 0.04) but less MACCE (8.7% vs. 13.6%, p = 0.02) than DAT and the use of DOAC was significantly associated to less bleeding (8% vs. 11.1%, p = 0.03) and similar MACCE (9.8% vs. 9.4%, p = 0.8). TAT over 1 month or with VKA was associated with more major bleeding but comparable MACCE rates. CONCLUSIONS: Despite advanced age TAT prevails, but duration over 1 month or the use of other agent than Apixaban are associated with increased bleeding without additional MACCE prevention. DAT reduces bleeding but with a trade-off in terms of ischemic events. DOAC use was significantly associated to less bleeding and similar MACCE rates.


Subject(s)
Atrial Fibrillation , Drug-Eluting Stents , Percutaneous Coronary Intervention , Aged , Anticoagulants/adverse effects , Atrial Fibrillation/diagnosis , Atrial Fibrillation/drug therapy , Atrial Fibrillation/epidemiology , Female , Fibrinolytic Agents/adverse effects , Humans , Male , Platelet Aggregation Inhibitors , Registries , Retrospective Studies , Stents
6.
PLoS One ; 14(5): e0216597, 2019.
Article in English | MEDLINE | ID: mdl-31063473

ABSTRACT

The open access availability of publications by Catalonia's CERCA research centres was analysed to determine the extent to which authors use open access journals, repositories, social networks and other websites to disseminate their research results. A sample of 3,730 journal articles published by authors from CERCA research centres between 2011 and 2015 and available on Web of Science (out of a total output of 44,423) was analysed to identify how many were available in open access, full-text format. The results revealed that 75,8% of the total (2,828 articles) had at least one version available in open access, but just 52% (1,940 articles) had at least one version available in either journals (whether pure or hybrid open access journals or those with embargo periods) or repositories, a finding that highlights the powerful role played by academic social networks in the sharp increase in open access availability. Of the 2,828 articles for which at least one open access version was found, a total of 9,868 copies were located. With respect to versions, the publisher's final version, i.e. the type formatted for publication by journal publishers, was found in 75,3% of cases. The number of articles published in open access journals (567) was very close to the number of articles published in hybrid journals or journals with embargo periods (624). Only 40,4% of the articles in the sample were located in repositories, being the subject repositories the heaviest used. Fifty percent of the articles (1,881 publications) were posted on academic social networks, the most popular of which were ResearchGate and Academia. According to thematic areas, all six areas (science, life sciences, medical and health sciences, engineering and architecture and humanities) exceeded 70% of articles in open access.


Subject(s)
Access to Information , Bibliometrics , Biomedical Research , Information Dissemination/methods , Internet/statistics & numerical data , Periodicals as Topic/statistics & numerical data , Publishing/trends , Humans , Spain , Time Factors
7.
Lab Anim ; 46(3): 220-4, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22511733

ABSTRACT

The ideal animal model would contribute no confounding variables in experimental science. Variables affect experimental design resulting in increased animal use or repeated studies. We demonstrated a simple refinement which may reduce the number of animals used experimentally while simultaneously improving animal welfare. The objective of this study was to determine if the presence of a hut was an impact on physiological stress levels, as determined by faecal cortisol concentration, during a routine four-day acclimatization period of newly received male Hartley-Outbred guineapigs. We hypothesized that those animals provided with huts would have decreased physiological stress compared with animals not provided with huts. We examined this effect within both paired and single-housed animals. A between-subjects one-way analysis of variance revealed that pair-housed animals with a hut had significantly lower faecal cortisol concentration than pair-housed animals without a hut and the presence and absence of a hut had no significant impact on faecal cortisol concentration in single-housed animals. These findings show that presence of a hut is beneficial in reducing physiological stress when pair housing male guineapigs and does not appear to have an impact when single housing male guineapigs. In addition, we have shown that faecal cortisol, and therefore physiological stress, is still increasing on study day 4 suggesting a longer acclimatization period is necessary. A simple refinement in housing environment and acclimatization time can both reduce the number of animals used experimentally and improve animal welfare.


Subject(s)
Animals, Laboratory/physiology , Guinea Pigs/physiology , Housing, Animal , Hydrocortisone/metabolism , Acclimatization , Animal Welfare , Animals , Enzyme-Linked Immunosorbent Assay , Feces/chemistry , Male , Quarantine , Stress, Physiological
8.
J Am Assoc Lab Anim Sci ; 49(1): 75-8, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20122321

ABSTRACT

Here we describe a case of zygomycosis in a 4-y-old male cynomolgus monkey (Macaca fascicularis) newly received into our facility. Results of physical exam, clinical chemistry analysis, hematology, and tuberculin skin testing and routine thoracic radiographs performed during the quarantine period are reported. Routine chest radiographs taken during the quarantine period revealed enlargement of the cranial mediastinum. During quarantine, the macaque developed severe respiratory distress and was euthanized. Microscopic examination of tissue collected at the postmortem exam revealed nonseptated, branching hyphae in sections of the stomach and mediastinal lymph nodes consistent with a zygomycete. This is the first reported case of zygomycosis in a cynomolgus monkey.


Subject(s)
Macaca fascicularis , Monkey Diseases/diagnosis , Zygomycosis/veterinary , Animals , Fatal Outcome , Male , Zygomycosis/diagnosis
9.
Arch. cardiol. Méx ; 77(supl.4): S4-16-S4-22, oct.-dic. 2007. ilus, graf
Article in Spanish | LILACS | ID: lil-568726

ABSTRACT

The mechanisms that regulate the stability of the atheroma plaque are a new focus of interest to understand the pathophysiology of acute coronary syndromes (ACS) and its therapy. Up to 75% of ACS are clinical expression of an unstable plaque rupture. The identification of unstable or so called vulnerable plaque (VP) became an interesting target, since they are the substrate of eventual future events. The VP determinant factors are: the size and consistence of lipid core, thickness of fibrous cap around this core, and the balance inflammation- reparation inside this cap. Inflammation plays a starring role in every single atherosclerosis stage. High sensitivity C - reactive protein (hs-CRP) is one of the most used markers of inflammation. We determined hs-CRP in 104 patients. The elevation of this marker was 5.85 mg/L in stable angina, 19.92 in non ST elevation ACS, and 50.41 mg/L in whom that presented ACS with ST elevation. (p < 0.01). The majority of coronary occlusion occurs in previously non-significant (< 70%) angiographic stenosis. Therefore, the current challenge is to identify and treat VP using whether invasive or non-invasive methods. This lead to a new concept: the [quot ]vulnerable patient[quot ]. Using these new diagnostic techniques, along with the information obtained from clinical trials in course, we should be able to prevent future coronary events.


Subject(s)
Humans , Acute Coronary Syndrome , Coronary Artery Disease , Inflammation , Rupture
10.
Arch Cardiol Mex ; 77 Suppl 4: S4-16-22, 2007.
Article in Spanish | MEDLINE | ID: mdl-18938692

ABSTRACT

The mechanisms that regulate the stability of the atheroma plaque are a new focus of interest to understand the pathophysiology of acute coronary syndromes (ACS) and its therapy. Up to 75% of ACS are clinical expression of an unstable plaque rupture. The identification of unstable or so called vulnerable plaque (VP) became an interesting target, since they are the substrate of eventual future events. The VP determinant factors are: the size and consistence of lipid core, thickness of fibrous cap around this core, and the balance inflammation- reparation inside this cap. Inflammation plays a starring role in every single atherosclerosis stage. High sensitivity C - reactive protein (hs-CRP) is one of the most used markers of inflammation. We determined hs-CRP in 104 patients. The elevation of this marker was 5.85 mg/L in stable angina, 19.92 in non ST elevation ACS, and 50.41 mg/L in whom that presented ACS with ST elevation. (p < 0.01). The majority of coronary occlusion occurs in previously non-significant (< 70%) angiographic stenosis. Therefore, the current challenge is to identify and treat VP using whether invasive or non-invasive methods. This lead to a new concept: the "vulnerable patient". Using these new diagnostic techniques, along with the information obtained from clinical trials in course, we should be able to prevent future coronary events.


Subject(s)
Acute Coronary Syndrome/complications , Coronary Artery Disease/etiology , Inflammation/complications , Humans , Rupture
SELECTION OF CITATIONS
SEARCH DETAIL
...